Treatment with the chemical chaperone 4-phenylbutyric acid partially restored GBM abnormalities in mild Alport syndrome organoids, whereas an exon-skipping strategy using antisense oligonucleotides restored expression of the C-terminal region of COL4A5 in vitro [51]. This evidence concerns the gene COL4A5 and Alport syndrome.